STENOCARE Celebrates Denmark’s Permanent Legalisation of Medical Cannabis
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
Today, the Danish parliament formally agreed on permanent legalisation of medical cannabis. This is fantastic news for both Danish patients and Stenocare, as it ensures continued access to and the sale of medical cannabis in Denmark
The Ministry of Interior and Health announced today that the political parties have decided to permanently legalise treatment with medical cannabis in Denmark. When the Danish Pilot Programme expires in December 2025, the Danish Parliament will enact legislation to ensure the permanent legalisation of medical cannabis treatment for patients. This is fantastic news for Danish patients, who now have certainty that they can continue their treatment. For Stenocare, it also provides a positive outlook for the Danish domestic market, where the company has been a leading supplier of prescription medical cannabis since 2018.
The Minister of Interior and Health, Sophie Løhde, commented on today’s agreement:
"Medical cannabis has proven to be a sought-after alternative to authorised medication for patients with serious diseases such as cancer and multiple sclerosis. Many experiences relief from pain or nausea that can significantly improve their quality of life. And with this agreement, we ensure that patients who have not had sufficient effect from other treatments will continue to be able to be prescribed medical cannabis by a doctor in a safe environment.”
The political parties also agreed to enhance information and guidance for both doctors and patients. This includes providing treatment guidelines for doctors and permitting patients to continue driving while undergoing treatment with medical cannabis. Stenocare views this as a significant victory for Danish patients, the company, and the medical cannabis industry, as it helps to normalise medical cannabis treatment and position it alongside other forms of medication.
Stenocare CEO, Thomas Skovlund Schnegelsberg, commented:
“Since 2017, Stenocare’s mission has been to improve the quality of life for patients in need of treatment for severe illnesses. In Denmark, the Pilot Programme has allowed patients to benefit from medical cannabis treatment, and we view the decision to permanently legalise medical cannabis as a strong endorsement of our mission. We are very pleased that medical cannabis is now officially recognised as part of the treatment regime in Denmark.”
Read the official press release from the Minister of Interior and Health (only in Danish): Ny aftale: Ordning med medicinsk cannabis på recept bliver permanent | Indenrigs- og Sundhedsministeriet
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
About STENOCARE A/S
STENOCARE A/S, founded in 2017, supplies prescription-based medical cannabis to patients in Denmark and internationally. It was the first company to receive permission from the Danish Medicines Agency to import, distribute, cultivate, and produce medical cannabis. Today, STENOCARE sources its products from a selection of high-quality international suppliers that comply with the strict European Good Manufacturing Practices (EU-GMP). STENOCARE has developed a unique patented medical cannabis oil product, ASTRUM, which provides improved bioavailability of active ingredients for patients. The company has strategically invested in assets to operate within the highly regulated pharmaceutical industry, with products approved for sale in multiple countries.
www.stenocare.com www.stenocare.dk www.stenocare.se